Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.
Division of Pathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Cells. 2021 Jun 2;10(6):1377. doi: 10.3390/cells10061377.
Despite the remarkable advances in the diagnosis and treatment of breast cancer patients, the presence or development of metastasis remains an incurable condition. Bone is one of the most frequent sites of distant dissemination and negatively impacts on patient's survival and overall frailty. The interplay between tumor cells and the bone microenvironment induces bone destruction and tumor progression. To date, the clinical management of bone metastatic breast cancer encompasses anti-tumor systemic therapies along with bone-targeting agents, aimed at slowing bone resorption to reduce the risk of skeletal-related events. However, their effect on patients' survival remains controversial. Unraveling the biology that governs the interplay between breast neoplastic cells and bone tissue would provide means for the development of new therapeutic agents. This article outlines the state-of-the art in the characterization and targeting the bone metastasis in breast cancer, focusing on the major clinical and translational studies on this clinically relevant topic.
尽管在乳腺癌患者的诊断和治疗方面取得了显著进展，但转移的存在或发展仍然是无法治愈的。骨骼是远处转移最常见的部位之一，会对患者的生存和整体虚弱状况产生负面影响。肿瘤细胞与骨微环境之间的相互作用会导致骨质破坏和肿瘤进展。迄今为止，骨转移乳腺癌的临床治疗方法包括抗肿瘤全身治疗和骨靶向药物，旨在减缓骨质吸收以降低骨骼相关事件的风险。然而，它们对患者生存的影响仍存在争议。阐明控制乳腺癌肿瘤细胞与骨组织相互作用的生物学机制将为开发新的治疗药物提供手段。本文概述了乳腺癌骨转移的特征和靶向治疗的最新进展，重点介绍了这一临床相关课题的主要临床和转化研究。
